Payment overview · 2025
General Payments
$196.72
10 reported records · 7 companies
Healthcare provider profile · identity verified
Gideon Griffeth Lewis, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WINTER PARK, FL · NPI 1508845116
Verified facts
What the public records show
CMS Open Payments records show Gideon Griffeth Lewis, M.D. received $196.72 in general payments during 2025 across 10 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.70 | 25.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.68 | 20.7% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $37.47 | 19.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.41 | 9.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.31 | 9.3% | 1 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $16.86 | 8.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.29 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $196.72 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $40.68 | 2 | 2025 |
Source payment records
|
|||||
| Bone Anchors with Arthroscopic Delivery System Normalized: bone anchors with arthroscopic delivery system |
Device | Smith+Nephew, Inc. | $37.47 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| DERMABOND Normalized: dermabond |
Device | Ethicon US, LLC | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| MONOCRYL Normalized: monocryl |
Device | Ethicon US, LLC | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| STRATAFIX Normalized: stratafix |
Device | Ethicon US, LLC | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| VICRYL Normalized: vicryl |
Device | Ethicon US, LLC | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 302 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 285 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 215 | 66 |
| Metformin Hcl | Metformin Hcl | 187 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 160 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 150 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 45 |
| Gabapentin | Gabapentin | 126 | 34 |
| Simvastatin | Simvastatin | 120 | 35 |
| Lisinopril | Lisinopril | 106 | 32 |
| Alprazolam | Alprazolam | 104 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 24 |
| Clonazepam | Clonazepam | 86 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 22 |
| Tramadol Hcl | Tramadol Hcl | 79 | 21 |
| Donepezil Hcl | Donepezil Hcl | 72 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 22 |
| Trazodone Hcl | Trazodone Hcl | 65 | 21 |
| Carvedilol | Carvedilol | 61 | 18 |
| Ezetimibe | Ezetimibe | 57 | 16 |
| Atenolol | Atenolol | 54 | 15 |
| Potassium Chloride | Potassium Chloride | 54 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Synthroid | Levothyroxine Sodium | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 42 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 12 |
| Furosemide | Furosemide | 40 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 13 |
| Meloxicam | Meloxicam | 39 | 16 |
| Omeprazole | Omeprazole | 39 | 15 |
| Ozempic | Semaglutide | 39 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 38 | suppressed |
| Jardiance | Empagliflozin | 37 | suppressed |
| Allopurinol | Allopurinol | 36 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 12 |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Prednisone | Prednisone | 32 | 21 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Indapamide | Indapamide | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 16 |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | 11 |
| Celecoxib | Celecoxib | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $196.72 · 10 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Bone Anchors with Arthroscopic Delivery System, Cologuard Collection Kit, DERMABOND, FARXIGA, MONOCRYL, MOUNJARO, REPATHA, STRATAFIX, TRELEGY ELLIPTA, VICRYL, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error